These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 8642360)

  • 1. Treatment of Parkinson's disease.
    Bergus G
    J Fam Pract; 1996 May; 42(5):457-8. PubMed ID: 8642360
    [No Abstract]   [Full Text] [Related]  

  • 2. [Drug therapy of Parkinson disease].
    Dietrichs E
    Tidsskr Nor Laegeforen; 1992 Oct; 112(24):3106-9. PubMed ID: 1471089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment.
    Knoll J
    Biomed Pharmacother; 1996; 50(6-7):315-7. PubMed ID: 8952875
    [No Abstract]   [Full Text] [Related]  

  • 4. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
    Rinne UK
    Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
    [No Abstract]   [Full Text] [Related]  

  • 5. Single vs multiple daily dosing of aminoglycosides.
    Newton W
    J Fam Pract; 1996 May; 42(5):456-7. PubMed ID: 8642359
    [No Abstract]   [Full Text] [Related]  

  • 6. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
    Amato L; Nava L; Rizzo M; Piccoli F
    Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinson's disease in the elderly: current management strategies.
    Aminoff MJ
    Geriatrics; 1987 Jul; 42(7):31-7. PubMed ID: 3110015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
    Olanow CW; Godbold JH; Koller W
    BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
    [No Abstract]   [Full Text] [Related]  

  • 11. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
    Stryjer R; Klein C; Treves TA; Rabey JM
    Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Daily defined doses of parkinsonian drugs in Alcoi].
    Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
    Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapy for patients with early-stage Parkinson's disease].
    Tanaka M; Okamoto K
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1426-31. PubMed ID: 13677890
    [No Abstract]   [Full Text] [Related]  

  • 14. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies in the treatment of early Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1993; 146():50-3. PubMed ID: 8101417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y; Kondo T; Takubo H; Yokochi F
    No To Shinkei; 1996 May; 48(5):467-72. PubMed ID: 8672306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    Adv Neurol; 1993; 60():672-5. PubMed ID: 8420208
    [No Abstract]   [Full Text] [Related]  

  • 18. Selegiline and mortality in Parkinson's disease.
    Olanow CW; Fahn S; Langston JW; Godbold J
    Ann Neurol; 1996 Dec; 40(6):841-5. PubMed ID: 9007088
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changing drug therapy of Parkinson disease].
    Rinne UK
    Duodecim; 1993; 109(20):1763-8. PubMed ID: 7736999
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.